

**LIBELED:** 5-16-61, Dist. P.R.

**CHARGE:** 503(b)(4)—when shipped, the articles were subject to 503(b)(1) and their labels failed to bear the statement "Caution: Federal law prohibits dispensing without prescription."

**DISPOSITION:** 8-3-61. Default—destruction.

**6789. Hy-Jet Wafers, Medcol Cotabs, and Medatinic tablets.** (F.D.C. No. 45895. S. Nos. 31-330 R, 31-332/3 R.)

**QUANTITY:** 17,580 *Hy-Jet Wafers* in btls. of 12 wafers, 24 wafers, and 500 wafers; 50,000 tablets of *Medcol Cotabs* in bulk containers and an undetermined number of 100-tablet btls. of *Medcol Cotabs*; and approximately 20,000 tablets of *Medatinic tablets* in 100-tablet btls., at New Orleans, La., in possession of Medco Co., Inc.

**SHIPPED:** The *Hy-Jet Wafers* were shipped on 2-12-60, from Gardena, Calif., by S. O. Barnes & Son, Inc.; and the other articles were shipped by a different firm, from Memphis, Tenn., on 12-11-59 and 12-28-59.

**LABEL IN PART:** (Btl.) "A New Concept in Feminine Hygiene *Hy-Jet Wafers* \* \* \* buffered to maintain an acid condition in the vaginal mucosa \* \* \* Medco Company, Inc., New Orleans, Louisiana"; "100 Cotabs MEDCOL \* \* \* Each Cotab contains: Pyrilamine Maleate 4 mg., Metapyrilene HCl 4 mg. \* \* \* Caution:"; and "100 Tablets Medatinic 500 Mg. Each Tablet Contains: Nicotinic Acid 500 Mg. (Niacin) \* \* \* Mfg. for Medco Co., Inc., New Orleans, La."

**RESULTS OF INVESTIGATION:** Analysis of the *Hy-Jet Wafers* showed that they contained boric acid and phenylmercuric borate in an effervescent base. The other articles were assumed to contain the ingredients listed on their labels. The *Medcol Cotabs* and the *Medatinic tablets* contained in the bottles had been repacked by the dealer from bulk containers shipped as described above.

**LIBELED:** 5-24-61, E. Dist. La.

**CHARGE:** 502(a)—when shipped, the label of the *Hy-Jet Wafers* contained false and misleading representations that the article was adequate and effective for the treatment of monilia, trichomonas, staphylococcus, and streptococcus infections of the vaginal tract; and 503(b)(4)—while held for sale, the label of the *Medcol Cotabs* bore the statement "Caution: Federal law prohibits dispensing without prescription," and the article was not subject to 503(b)(1); and 503(b)(4)—while held for sale, the *Medatinic tablets* were a drug subject to 503(b)(1) and their label failed to bear the statement "Caution: Federal law prohibits dispensing without prescription."

**DISPOSITION:** *Medcol Cotabs* and *Medatinic tablets*, 6-29-61. Consent—claimed by Medco Co., Inc., and released under bond for relabeling. *Hy-Jet Wafers*, 7-14-61. Default—destruction.

**6790. Vigosan tablets.** (F.D.C. No. 45898. S. Nos. 32-272/3 R, 32-283/4 R.)

**QUANTITY:** 323 25-tablet btls. and 78 50-tablet btls. at San Juan, P.R.

**SHIPPED:** 3-10-61 and 4-25-61, from New York, N.Y., by Gold Leaf Pharmacal Co., Inc.

**LABEL IN PART:** "Vigosan \* \* \* Gold Leaf Pharmacal Co., Inc., New Rochelle, N.Y. \* \* \* Each tablet contains: Testosterone 2 mgm. Yohimbine HCl. 5 mgm. Vitamin E 10 mgm. Extract Damiana 60 mgm. Extract Nux Vomica 5 mgm. Dosage: One or two tablets 3 times daily."